Progression or relapse of FL within 2 years after diagnosis (a phenomenon known as POD24) is associated with a poor outcome for patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone).
Although many patients with FL have an indolent, relapsing-remitting disease course, as well as a favorable prognosis, approximately 20% experience early disease progression after initial treatment with chemoimmunotherapy. Patients with POD24 are enriched for mutations in KMT2C, TP53, BTG1, MKI67, XBP1, SOCS1, IKZF3, B2M, FAS, and MYD88.
Learn more about the practice essentials of FL.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Progression of Follicular Lymphoma - Medscape - Nov 10, 2021.